{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T12:49:25Z","timestamp":1780663765630,"version":"3.54.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2005,7,1]],"date-time":"2005-07-01T00:00:00Z","timestamp":1120176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2005,7]]},"DOI":"10.1016\/j.diagmicrobio.2005.05.004","type":"journal-article","created":{"date-parts":[[2005,8,15]],"date-time":"2005-08-15T11:05:49Z","timestamp":1124103949000},"page":"187-193","source":"Crossref","is-referenced-by-count":72,"title":["Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia"],"prefix":"10.1016","volume":"52","author":[{"given":"Thomas R.","family":"Fritsche","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helio S.","family":"Sader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew G.","family":"Stilwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Dowzicky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald N.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2005.05.004_bib1","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/jac\/dkf196","article-title":"Comparative in vitro activities of tigecycline (GAR-936) and other antimicrobial agents against Stenotrophomonas maltophilia","volume":"50","author":"Betriu","year":"2002","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2005.05.004_bib2","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1093\/jac\/dki096","article-title":"In vitro activity of tigecycline against ampicillin-resistant Haemophilus influenzae isolates","volume":"55","author":"Betriu","year":"2005","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2005.05.004_bib3","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0732-8893(01)00269-3","article-title":"In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant Gram-positive bloodstream infection isolates and strains producing extended-spectrum \u03b2-lactamases","volume":"40","author":"Biedenbach","year":"2001","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2005.05.004_bib4","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.diagmicrobio.2004.11.006","article-title":"In vitro evaluation of tigecycline and comparative agents in 3,049 clinical isolates: 2001 to 2002","volume":"51","author":"Bouchillon","year":"2005","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2005.05.004_bib5","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.clinmicnews.2004.10.001","article-title":"Tigecycline: a first in class glycylcycline","volume":"26","author":"Bradford","year":"2004","journal-title":"Clin. Microbiol. Newsl."},{"key":"10.1016\/j.diagmicrobio.2005.05.004_bib6","series-title":"Performance standards for antimicrobial susceptibility testing, 15th informational supplement, M100-S15","author":"Clinical Laboratory Standards Institute","year":"2005"},{"key":"10.1016\/j.diagmicrobio.2005.05.004_bib7","article-title":"Results of a phase 3, double-blind, safety and efficacy study comparing tigecycline with vancomycin\/aztreonam to treat complicated skin and skin structure infections","author":"Dartois","year":"2004"},{"key":"10.1016\/j.diagmicrobio.2005.05.004_bib8","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1128\/AAC.47.2.533-540.2003","article-title":"Activities of tigecycline (GAR-936) against Legionella pneumophila in vitro and in guinea pigs with L. pneumophila pneumonia","volume":"47","author":"Edelstein","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2005.05.004_bib9","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1046\/j.1469-0691.2000.00034-6.x","article-title":"In vitro susceptibility of anaerobic bacteria to GAR-936, a new glycylcycline","volume":"6","author":"Edlund","year":"2000","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.diagmicrobio.2005.05.004_bib10","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s100960100455","article-title":"Frequency of isolation of pathogens from bloodstream, nosocomial pneumonia, skin and soft tissue and urinary tract infections occurring in European patients","volume":"20","author":"Fluit","year":"2001","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2005.05.004_bib11","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S1201-9712(02)90077-9","article-title":"Antimicrobial resistance among isolates cultured from patients hospitalized with lower respiratory tract infection in Europe","volume":"6","author":"Fluit","year":"2002","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2005.05.004_bib12","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.diagmicrobio.2004.03.002","article-title":"In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and Gram-positive cutaneous infections","volume":"49","author":"Fritsche","year":"2004","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2005.05.004_bib13","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0732-8893(02)00499-6","article-title":"Respiratory tract pathogens isolated from patients hospitalized with suspected pneumonia in Latin America: frequency of occurrence and antimicrobial susceptibility profile: results from the SENTRY Antimicrobial Surveillance Program (1997\u20132000)","volume":"44","author":"Gales","year":"2002","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2005.05.004_bib14","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0732-8893(03)00087-7","article-title":"Comparison of Streptococcus pneumoniae and Haemophilus influenzae susceptibilities from community-acquired respiratory tract infections and hospitalized patients with pneumonia: five-year results for the SENTRY Antimicrobial Surveillance Program","volume":"46","author":"Gordon","year":"2003","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2005.05.004_bib15","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1093\/jac\/49.3.479","article-title":"Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936)","volume":"49","author":"Henwood","year":"2002","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2005.05.004_bib16","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0732-8893(02)00540-0","article-title":"Pathogen occurrence and susceptibility patterns associated with pneumonia in hospitalized patients in North America: results of the SENTRY Antimicrobial Surveillance Program (2000)","volume":"45","author":"Hoban","year":"2003","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2005.05.004_bib17","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1128\/AAC.44.4.1085-1088.2000","article-title":"Antipneumococcal activities of GAR-936 (a new glycylcycline) compared to those of nine other agents against penicillin-susceptible and -resistant pneumococci","volume":"44","author":"Hoellman","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2005.05.004_bib18","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1128\/AAC.48.3.1034-1036.2004","article-title":"In vitro activities of tigecycline against the Bacteroides fragilis group","volume":"48","author":"Jacobus","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2005.05.004_bib19","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0732-8893(99)00090-5","article-title":"Disk diffusion susceptibility test development for the new glycylcycline, GAR-936","volume":"35","author":"Jones","year":"1999","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2005.05.004_bib20","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1055\/s-2003-37923","article-title":"Global epidemiology of antimicrobial resistance among community-acquired and nosocomial pathogens: A five-year summary from the SENTRY Antimicrobial Surveillance Program (1997\u20132001)","volume":"24","author":"Jones","year":"2003","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"10.1016\/j.diagmicrobio.2005.05.004_bib21","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1128\/AAC.45.9.2604-2608.2001","volume":"45","author":"Kenny","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2005.05.004_bib22","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1128\/AAC.48.1.366-367.2004","article-title":"In vitro activities of tigecycline (GAR-936) against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae","volume":"48","author":"Kitzis","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2005.05.004_bib23","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S0924-8579(02)00132-2","article-title":"Activity of GAR-936 and other antimicrobial agents against North American isolates of Staphylococcus aureus","volume":"20","author":"Low","year":"2002","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.diagmicrobio.2005.05.004_bib24","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1128\/AAC.47.1.400-404.2003","article-title":"Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates","volume":"47","author":"Milatovic","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2005.05.004_bib25","article-title":"The clinical response to tigecycline in the treatment of complicated intra-abdominal infections in hospitalized patients. A phase 2 clinical trial","author":"Murray","year":"2003"},{"key":"10.1016\/j.diagmicrobio.2005.05.004_bib26","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ijantimicag.2004.11.006","article-title":"Tigecycline: clinical evidence and formulary positioning","volume":"25","author":"Nathwani","year":"2005","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.diagmicrobio.2005.05.004_bib27","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-sixth edition","author":"National Committee for Clinical Laboratory Standards","year":"2003"},{"key":"10.1016\/j.diagmicrobio.2005.05.004_bib28","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.ajic.2003.09.002","article-title":"National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003","volume":"31","author":"National Nosocomial Infections Surveillance (NNIS)","year":"2003","journal-title":"Am. J. Infect. Control."},{"key":"10.1016\/j.diagmicrobio.2005.05.004_bib29","doi-asserted-by":"crossref","first-page":"4479","DOI":"10.1128\/AAC.48.11.4479-4481.2004","article-title":"Activity of tigecycline (GAR-936) against Acinetobacter baumannii strains","volume":"48","author":"Pachon-Ibanez","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2005.05.004_bib30","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0732-8893(00)00193-0","article-title":"In vitro activity of GAR-936 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae","volume":"38","author":"Patel","year":"2000","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2005.05.004_bib31","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/S0149-2918(04)90070-7","article-title":"Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients","volume":"26","author":"Postier","year":"2004","journal-title":"Clin. Ther."},{"key":"10.1016\/j.diagmicrobio.2005.05.004_bib32","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0924-8579(00)00198-9","article-title":"In vitro activity of GAR-936 against Chlamydia pneumoniae and Chlamydia trachomatis","volume":"16","author":"Roblin","year":"2000","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.diagmicrobio.2005.05.004_bib35","author":"Tygacil Product Insert","year":"2005"},{"key":"10.1016\/j.diagmicrobio.2005.05.004_bib33","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMp048093","article-title":"The antibiotic pipeline\u2014challenges, costs and values","volume":"351","author":"Wenzel","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.diagmicrobio.2005.05.004_bib34","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2165\/00003495-200464010-00005","article-title":"The glycylcyclines: a comparative review with the tetracyclines","volume":"64","author":"Zhanel","year":"2004","journal-title":"Drugs"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889305001318?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889305001318?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,23]],"date-time":"2019-01-23T18:53:31Z","timestamp":1548269611000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889305001318"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,7]]}},"alternative-id":["S0732889305001318"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2005.05.004","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2005,7]]}}}